1. Home
  2. Labeler Index
  3. Preferred Pharmaceuticals Inc.
  4. 68788-8577
  5. Product Images: Levetiracetam

Product Images Levetiracetam

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 8 images provide visual information about the product associated with Levetiracetam NDC 68788-8577 by Preferred Pharmaceuticals Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1

This figure shows the Responder Rate with a 250% reduction from the baseline in Study 1. The graph displays percentages ranging from 0% to 39.6%, with some points signifying statistical significance versus placebo.*

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2

This is a evaluation of the Responder Rate in Study 2, comparing the effects of Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day on patients. The Responder Rate represents a 250% reduction from the baseline. It shows the percentage of patients who responded positively to the treatment. The results indicate that Levetiracetam 2000 mg/day had a statistically significant effect compared to the placebo.*

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3

This text provides a figure showing the Responder Rate (>50% Reduction from Baseline) in Study 3. The data compares the responder rates of a placebo group (N=104) with a group receiving Levetiracetam 3000 mg/day (N=180). It indicates that the Levetiracetam group had a statistically significant improvement compared to the placebo group.*

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4

This text provides information about the Responder Rate in Study 4, showing a 50% reduction from baseline. It includes percentages for the placebo group (44.6%) and the levetiracetam group (45%). Additionally, it mentions that levetiracetam was statistically significant versus placebo.*

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5

This text discusses the Responder Rate for patients aged 1 month to less than 4 years in Study 5, showing a more than 50% reduction from baseline with the medication Lovetracatam. The results indicate that Lovetracatam was statistically significant compared to a placebo in achieving this reduction.*

Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6

Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6

This figure shows the Responder Rate (250% Reduction from Baseline) in Primary Generalized Tonic-Clonic (PGTC) seizure frequency per week in Study 7. The graph compares the placebo group (N=84) with the levetiracetam group (N=79). The percentage of patients responding to treatment is shown with a significant increase noted in the levetiracetam group compared to placebo.*

Levetiracetam Tab USP 500mg - levetiracetam fig9

Levetiracetam Tab USP 500mg - levetiracetam fig9

This is a description of Levetiracetam tablets, a generic for Keppra, in 500mg strength. The tablets are film-coated and oval, yellow in color, with imprint E 1T. They are to be stored at 20°-25°C and kept out of reach of children. The package contains information on the expiration date, lot number, batch number, and manufacturer details. The text also provides cautions about the transfer of the drug and includes dosage instructions in both English and Spanish. The tablets are available by prescription only and the label includes billing chart log information.*

Chemical Structure - levetiracetam str

Chemical Structure - levetiracetam str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.